Investigation and Analysis of Nutritional Status of Patients With Lung Cancer

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Palliative Care
Thoracic Malignancies
Presenter Xiao Chen
Citation Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425
Authors X. Chen, L. Zhang, X. Liu
  • Cancer Center, THE FIRST AFFILIATED HOSPITAL JILIN UNIVERSITY, 510008 - Changchun/CN

Abstract

Background

The occurrence rate of malnutrition, leading cancer-related mortality, in malignant tumor patients reaches up to 40%-80%. Early assessment of nutritional status and timely nutritional intervention is of significance in patients with lung cancer. It’s necessary to evaluating the nutritional status of patients with lung cancer and seeking out the possible factors during hospitalization.

Methods

2388 cases and their basic characteristics(age, gender, BMI , KPS and PG-SGA scores), features of tumor(cTNM, histological types, Tumor treatment) were obtained and analyzed. Relationships between PG-SGA and the others were analyzed by Logistic regression analysis.

Results

Among 2388 patients with lung cancer, the malnutrition rate was 54.6%. Among them, 533 cases were severe malnutrition, accounting for 22.3%; 771 cases were moderate malnutrition, accounting for 32.3% Logistic regression analysis showed that the following characteristics were associated by a greater likelihood of PG-SGA≥9 or malnutrition: age, tumor staging and treatment mode; those independent risk factors for malnutrition. The higher the BMI and KPS scores, the lower the risk of malnutrition, which is also the protective factor(P < 0.05).

Conclusions

The results of this study confirm that the occurrence of malnutrition in patients with lung cancer during the hospital stay is relatively high. Doctor should pay increasing attention to the age, tumor staging, treatment, and provide nutrition counseling and nutrition intervention as early as possible, to reduce incidence the of malnutrition.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Chenxiao.

Funding

Has not received any funding.

Disclosure

X. Chen, X. Liu, L. Zhang: There is no financial interest in products or processes involved in the research.